AA
AGIO icon

AlphaCentric Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

AlphaCentric Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$473K Buy
13,971
+830
+6% +$23.5K 0.47% 67
2025
Q4 		$358K Buy
+13,141
New +$461K 0.36% 91
2024
Q4 		$202K Buy
+6,140
New +$288K 0.2% 118
2022
Q4 		– Sell
-15,000
Closed -$424K – 168
2022
Q3 		$424K Buy
+15,000
New +$402K 0.44% 64
2021
Q4 		$378K Buy
+11,500
New +$463K 0.11% 74

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

AlphaCentric Advisors's AGIO Position: Q1 2026 in Review

AlphaCentric Advisors increased its Agios Pharmaceuticals (AGIO) stake by 6.3% in Q1 2026, buying an estimated $23.5K and bringing the position to 13,971 shares worth $473K. The position accounts for 0.47% of the portfolio, ranked #67.

AlphaCentric Advisors first reported a position in AGIO in Q4 2021 and has held it in 5 quarters since. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • AlphaCentric Advisors held 13,971 shares of Agios Pharmaceuticals worth $473K as of Q1 2026.
  • AlphaCentric Advisors bought 830 Agios Pharmaceuticals shares in Q1 2026, an estimated $23.5K.
  • Agios Pharmaceuticals made up 0.47% of AlphaCentric Advisors's portfolio in Q1 2026, its #67 holding.
  • AlphaCentric Advisors first reported a position in Agios Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.